BIIB - Biogen Inc.
After hours:
| Previous close | 302.41 |
| Open | 302.53 |
| Bid | 300.00 x 800 |
| Ask | 301.25 x 800 |
| Day's range | 297.68 - 303.17 |
| 52-week range | 188.54 - 319.74 |
| Volume | |
| Avg. volume | 916,847 |
| Market cap | 43.452B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 13.70 |
| EPS (TTM) | 21.92 |
| Earnings date | 18 Jul 2023 - 24 Jul 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 332.78 |
ZacksIonis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Simply Wall St.Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company
Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...
ZacksAlkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksBiogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Motley Fool1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
- Simply Wall St.
Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 29% Above Its Share Price
Key Insights Biogen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Biogen's US$306 share...
ZacksHere's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
GlobeNewswireHealth Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cogniti
Motley FoolThese 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
Motley Fool3 Reasons to Buy Biogen Stock (and 1 to Sell)
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.
Motley FoolHere's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
- Simply Wall St.
Biogen's (NASDAQ:BIIB) investors will be pleased with their favorable 64% return over the last year
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
ZacksDenali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
ZacksIonis (IONS) Q1 Earnings Surpass Estimates, Sales Match
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
- Simply Wall St.
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what...
Yahoo FinanceEli Lilly: Positive results on its new Alzheimer's drug
Eli Lilly stock is up on news that its new Alzheimer's drug showed reduction in cognitive decline.
- Simply Wall St.
Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 87% of the company
Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...
Yahoo Finance VideoDrugmakers brace for serious headwinds ahead
Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.
ZacksThe Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
ZacksBiotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
- GlobeNewswire
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal,2 and ultra-rare genetic form of ALS3-4 with approximately 330 people in the U.S. living with the disease5 CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 10
ZacksBiogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
ZacksBiogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksBiogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?